LXS196 - CAS# 1874276-76-2 60100 Co-crystal structures showed that PFI-1

Co-crystal structures showed that PFI-1 acts as an acetyl-lysine (Kac) mimetic inhibitor efficiently occupying the Kac binding site in BRD2 and BRD4

Characterization of Sugar Contents and Sucrose Metabolizing Enzymes in Developing Leaves of Hevea brasiliensis

7 uM (cellular inhibition of phospho-Ser916-PKD1 activity) [1] Target: PKD CID 2011756

PubMed Central PMCID: PMC4226443

identified by a high-throughput screening

LXS196 - CAS# 1874276-76-2 60100 Co-crystal structures showed that PFI-1LXS196, CAS No. 1874276 76 2, is a potent and orally active protein kinase C inhibitor for the treatment of uveal melanoma. Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine threonine protein kinase overexpressed in certain types of cancer